By week 24, bowel exams showed remission in 40.5% of patients on AbbVie’s experimental Crohn’s treatment.

AbbVie (ABBV) reported positive Phase 2a trial results for ABBV-466, a dual-target therapy for Crohn’s disease, showing superior remission rates. The company has a 2.34% dividend yield, 85% payout ratio, and trades 28.3% above its GF Value™ of $222.50. Insiders have sold $17.7M in shares, while gurus show mixed interest.

AbbVie (ABBV) announced that its investigational therapy ABBV-466 showed higher endoscopic remission rates in Crohn's disease patients than either anti-IL-23 or anti-α4β7 monotherapy in a Phase 2a study. The results will be presented at the 2026 UEGW Congress. ABBV-466 demonstrated tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes at Week 24. The study included 300 patients with moderate to severe Crohn's disease.

AbbVie's Phase 2a study of ABBV-466, a dual-targeting therapy for Crohn's disease, showed higher remission rates than its components alone. At Week 12, 30.2% of patients achieved remission, rising to 40.5% by Week 24. The study included 300 patients, many of whom had failed prior therapies. ABBV-466 combines risankizumab and trosunilimab. The stock closed at $285.42 on October 16, 2026, and was down 0.17% in pre-market trading.

AbbVie (ABBV) reported that its experimental drug ABBV-466 showed higher endoscopic remission rates in Crohn's disease patients than either anti-IL-23 or anti-α4β7 monotherapy at Weeks 12 and 24 in a Phase 2a study. The findings were presented at the 2026 UEGW Congress.

AbbVie (NYSE: ABBV) announced it will present data on seven oncology assets at the 2026 ESMO Congress. Key findings include Temab-A's 30% ORR in colorectal cancer and 50% ORR in lung cancer, ABBV-706's 56% ORR in SCLC, and ABBV-969's 90% ctDNA reduction in prostate cancer. The company highlights its largest ESMO presence to date, showcasing progress in solid tumor treatments.

AbbVie (ABBV) will present data on seven oncology assets at the 2026 ESMO Congress, highlighting progress in lung, colorectal, ovarian, prostate, and gastric cancers. Key findings include Temab-A's 30% ORR in CRC and 50% ORR in NSCLC, ABBV-706's 56% ORR in SCLC, and ABBV-969's 90% ctDNA reduction in mCRPC. The company aims to showcase its solid tumor portfolio's potential.